Step Therapy Criteria
Updated 10/2019

ACYCLOVIR OINT (CCHP2017)

Products Affected

Step 2:

- *acyclovir 5 % topical ointment*

Details

Criteria	Step Therapy requires trial of one (1) of the following: oral generic acyclovir, oral generic famciclovir, oral generic valacyclovir.

Step Therapy Criteria
Updated 10/2019

ALPHAGAN (CCHP2017)

Products Affected

Step 2:

- ALPHAGAN P 0.1 % EYE DROPS

Details

Criteria	Step Therapy requires trial of brimonidine 0.15%.

ANTIDEPRESSANT_NVT 2017

Products Affected

Step 2:

- DESVENLAFAXINE ER 100 MG TABLET,EXTENDED RELEASE 24 HR
- DESVENLAFAXINE ER 50 MG TABLET,EXTENDED RELEASE 24 HR
- DESVENLAFAXINE FUMARATE ER 100 MG TABLET, EXTENDED RELEASE 24 HR
- DESVENLAFAXINE FUMARATE ER 50 MG TABLET, EXTENDED RELEASE 24 HR
- *duloxetine 40 mg capsule,delayed release*
- EMSAM 12 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- EMSAM 6 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- EMSAM 9 MG/24 HR TRANSDERMAL 24 HOUR PATCH
- FETZIMA 120 MG CAPSULE,EXTENDED RELEASE
- FETZIMA 20 MG (2)-40 MG (26) CAPSULE,EXTENDED RELEASE,24 HR,DOSE PACK
- FETZIMA 20 MG CAPSULE,EXTENDED RELEASE
- FETZIMA 40 MG CAPSULE,EXTENDED RELEASE
- FETZIMA 80 MG CAPSULE,EXTENDED RELEASE
- *fluvoxamine er 100 mg capsule,extended release 24 hr*
- *fluvoxamine er 150 mg capsule,extended release 24 hr*
- MARPLAN 10 MG TABLET
- TRINTELLIX 10 MG TABLET
- TRINTELLIX 20 MG TABLET
- TRINTELLIX 5 MG TABLET
- VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK
- VIIBRYD 10 MG TABLET
- VIIBRYD 20 MG TABLET
- VIIBRYD 40 MG TABLET

Details

Criteria	Step Therapy requires trial of one of the following generic SSRI's in previous 120 days: escitalopram, sertraline, fluoxetine, citalopram, paroxetine, Paxil oral solution, or fluvoxamine. If request is for duloxetine, step not required for diabetic peripheral neuropathy, fibromyalgia, or chronic musculoskeletal pain.

Step Therapy Criteria
Updated 10/2019

ARICEPT 23_NVT 2015

Products Affected

Step 2:

- *donepezil 10 mg disintegrating tablet*
- *donepezil 5 mg disintegrating tablet*

Details

Criteria	Step Therapy requires trial of regular donepezil 5 mg or 10mg oral tablets in previous 120 days.

Step Therapy Criteria
Updated 10/2019

DEXILANT_2019

Products Affected

Step 2:

- DEXILANT 30 MG CAPSULE, DELAYED RELEASE
- DEXILANT 60 MG CAPSULE, DELAYED RELEASE

Details

Criteria	Step therapy requires trial of lansoprazole in the previous 120 days.

DPP4

Products Affected

Step 2:

- KOMBIGLYZE XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE
- KOMBIGLYZE XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE
- KOMBIGLYZE XR 5 MG-500 MG TABLET,EXTENDED RELEASE
- ONGLYZA 2.5 MG TABLET
- ONGLYZA 5 MG TABLET

Details

Criteria	ST Criteria: Pending CMS Approval

DRY EYE OTC (CCHP 2018)

Products Affected

Step 2:

- RESTASIS 0.05 % EYE DROPS IN A DROPPERETTE

Details

Criteria	Step Therapy requires trial of OTC artificial tears.

GLP1

Products Affected

Step 2:

- OZEMPIC 0.25 MG OR 0.5 MG (2 MG/1.5 ML) SUBCUTANEOUS PEN INJECTOR
- OZEMPIC 1 MG/DOSE (2 MG/1.5 ML) SUBCUTANEOUS PEN INJECTOR
- TRULICITY 0.75 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR
- TRULICITY 1.5 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR
- VICTOZA 3-PAK 0.6 MG/0.1 ML (18 MG/3 ML) SUBCUTANEOUS PEN INJECTOR

Details

Criteria	Step Therapy requires trial of METFORMIN in the past 120 days.

Step Therapy Criteria
Updated 10/2019

LAMA

Products Affected

Step 2:

- SPIRIVA RESPIMAT 1.25 MCG/ACTUATION SOLUTION FOR INHALATION
- SPIRIVA RESPIMAT 2.5 MCG/ACTUATION SOLUTION FOR INHALATION
- SPIRIVA WITH HANDIHALER 18 MCG AND INHALATION CAPSULES

Details

Criteria	Step Therapy requires trial of Incruse or Tudorza.

LAMA/LABA

Products Affected

Step 2:

- STIOLTO RESPIMAT 2.5 MCG-2.5 MCG/ACTUATION SOLUTION FOR INHALATION

Details

Criteria	Step Therapy requires trial of ANORO.

OPHTHALMIC ANTI-INFECTIVES_NVT 2015

Products Affected

Step 2:

- BESIVANCE 0.6 % EYE DROPS,SUSPENSION
- *gatifloxacin 0.5 % eye drops*

Details

Criteria	Step Therapy requires trial of one of the following ciprofloxacin, levofloxacin, or ofloxacinin previous 120 days.

Step Therapy Criteria
Updated 10/2019

PANCREATIC ENZYMES_NVT 2015

Products Affected

Step 2:

- PANCREAZE 10,500 UNIT-35,500 UNIT-61,500 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 16,800 UNIT-56,800 UNIT-98,400 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 2,600 UNIT-6,200 UNIT-10,850 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 21,000 UNIT-54,700 UNIT-83,900 UNIT CAPSULE,DELAYED RELEASE
- PANCREAZE 4,200 UNIT-14,200 UNIT-24,600 UNIT CAPSULE,DELAYED RELEASE

Details

Criteria	Step Therapy requires trial of CREON in previous 120 days.

POLYETHYLENE GLYCOL

Products Affected

Step 2:

- LINZESS 145 MCG CAPSULE
- LINZESS 290 MCG CAPSULE
- LINZESS 72 MCG CAPSULE
- MOVANTIK 12.5 MG TABLET
- MOVANTIK 25 MG TABLET
- RELISTOR 12 MG/0.6 ML SUBCUTANEOUS SOLUTION
- RELISTOR 12 MG/0.6 ML SUBCUTANEOUS SYRINGE
- RELISTOR 8 MG/0.4 ML SUBCUTANEOUS SYRINGE

Details

Criteria	ST Criteria: Pending CMS Approval

SGLT2

Products Affected

Step 2:

- INVOKAMET 150 MG-1,000 MG TABLET
- INVOKAMET 150 MG-500 MG TABLET
- INVOKAMET 50 MG-1,000 MG TABLET
- INVOKAMET 50 MG-500 MG TABLET
- INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE
- INVOKANA 100 MG TABLET
- INVOKANA 300 MG TABLET
- JARDIANCE 10 MG TABLET
- JARDIANCE 25 MG TABLET
- SYNJARDY 12.5 MG-1,000 MG TABLET
- SYNJARDY 12.5 MG-500 MG TABLET
- SYNJARDY 5 MG-1,000 MG TABLET
- SYNJARDY 5 MG-500 MG TABLET
- SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE

Details

Criteria	Step Therapy requires trial of METFORMIN in previous 120days.

Step Therapy Criteria
Updated 10/2019

ST_RIVASTIGMINE_2019

Products Affected

Step 2:

- *rivastigmine 13.3 mg/24 hour transdermal patch*
- *rivastigmine 4.6 mg/24 hour transdermal patch*
- *rivastigmine 9.5 mg/24 hour transdermal patch*

Details

Criteria	Step Therapy requires trial of rivastigmine tablets in past 120 days.

Step Therapy Criteria
Updated 10/2019

ST_SMOKINGCESS_2019

Products Affected

Step 2:

- *bupropion hcl 150 mg tablet,12 hr sustained-release(smoking deterrent)*

Details

Criteria	Step therapy requires trial of Nicoderm patches in previous 120 days.

Step Therapy Criteria
Updated 10/2019

ULORIC_NVT 2015

Products Affected

Step 2:

- *febuxostat 40 mg tablet*
- *febuxostat 80 mg tablet*
- ULORIC 40 MG TABLET
- ULORIC 80 MG TABLET

Details

Criteria	Step Therapy requires trial of allopurinol in previous 120 days.

Step Therapy Criteria
Updated 10/2019

ZADITOR OTC (CCHP2017)

Products Affected

Step 2:

- *olopatadine 0.1 % eye drops*

Step 3:

- *olopatadine 0.2 % eye drops*
- PAZEO 0.7 % EYE DROPS

Details

Criteria	Step Therapy requires trial of OTC zaditor/ketotifen for olopatadine ophth soln. Trial of olopatadine 1 mg/ml ophth soln required for olopatadine 2 mg/ml and PAZEO

INDEX

A
acyclovir 5 % topical ointment..... 1
ALPHAGAN P 0.1 % EYE DROPS..... 2
B
BESIVANCE 0.6 % EYE DROPS,SUSPENSION 11
bupropion hcl 150 mg tablet,12 hr sustained-release(smoking deterrent)..... 16
D
DESVENLAFAXINE ER 100 MG TABLET,EXTENDED RELEASE 24 HR 3
DESVENLAFAXINE ER 50 MG TABLET,EXTENDED RELEASE 24 HR 3
DESVENLAFAXINE FUMARATE ER 100 MG TABLET, EXTENDED RELEASE 24 HR..... 3
DESVENLAFAXINE FUMARATE ER 50 MG TABLET, EXTENDED RELEASE 24 HR..... 3
DEXILANT 30 MG CAPSULE, DELAYED RELEASE..... 5
DEXILANT 60 MG CAPSULE, DELAYED RELEASE..... 5
donepezil 10 mg disintegrating tablet..... 4
donepezil 5 mg disintegrating tablet..... 4
duloxetine 40 mg capsule,delayed release.. 3
E
EMSAM 12 MG/24 HR TRANSDERMAL 24 HOUR PATCH..... 3
EMSAM 6 MG/24 HR TRANSDERMAL 24 HOUR PATCH..... 3
EMSAM 9 MG/24 HR TRANSDERMAL 24 HOUR PATCH..... 3
F
febuxostat 40 mg tablet..... 17
febuxostat 80 mg tablet..... 17
FETZIMA 120 MG CAPSULE,EXTENDED RELEASE..... 3
FETZIMA 20 MG (2)-40 MG (26) CAPSULE,EXTENDED RELEASE,24 HR,DOSE PACK..... 3
FETZIMA 20 MG CAPSULE,EXTENDED RELEASE 3
FETZIMA 40 MG CAPSULE,EXTENDED RELEASE 3
FETZIMA 80 MG CAPSULE,EXTENDED RELEASE 3
fluvoxamine er 100 mg capsule,extended release 24 hr..... 3
fluvoxamine er 150 mg capsule,extended release 24 hr..... 3
G
gatifloxacin 0.5 % eye drops..... 11
I
INVOKAMET 150 MG-1,000 MG TABLET..... 14
INVOKAMET 150 MG-500 MG TABLET 14
INVOKAMET 50 MG-1,000 MG TABLET 14
INVOKAMET 50 MG-500 MG TABLET14
INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE 14
INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE 14
INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE 14
INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE 14
INVOKANA 100 MG TABLET..... 14
INVOKANA 300 MG TABLET..... 14
J
JARDIANCE 10 MG TABLET 14
JARDIANCE 25 MG TABLET 14
K
KOMBIGLYZE XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE 6
KOMBIGLYZE XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE 6

KOMBIGLYZE XR 5 MG-500 MG TABLET,EXTENDED RELEASE 6
L
LINZESS 145 MCG CAPSULE 13
LINZESS 290 MCG CAPSULE 13
LINZESS 72 MCG CAPSULE 13
M
MARPLAN 10 MG TABLET 3
MOVANTIK 12.5 MG TABLET 13
MOVANTIK 25 MG TABLET 13
O
olopatadine 0.1 % eye drops 18
olopatadine 0.2 % eye drops 18
ONGLYZA 2.5 MG TABLET 6
ONGLYZA 5 MG TABLET 6
OZEMPIC 0.25 MG OR 0.5 MG (2 MG/1.5 ML) SUBCUTANEOUS PEN INJECTOR 8
OZEMPIC 1 MG/DOSE (2 MG/1.5 ML) SUBCUTANEOUS PEN INJECTOR 8
P
PANCREAZE 10,500 UNIT-35,500 UNIT-61,500 UNIT CAPSULE,DELAYED RELEASE 12
PANCREAZE 16,800 UNIT-56,800 UNIT-98,400 UNIT CAPSULE,DELAYED RELEASE 12
PANCREAZE 2,600 UNIT-6,200 UNIT-10,850 UNIT CAPSULE,DELAYED RELEASE 12
PANCREAZE 21,000 UNIT-54,700 UNIT-83,900 UNIT CAPSULE,DELAYED RELEASE 12
PANCREAZE 4,200 UNIT-14,200 UNIT-24,600 UNIT CAPSULE,DELAYED RELEASE 12
PAZEO 0.7 % EYE DROPS 18
R
RELISTOR 12 MG/0.6 ML SUBCUTANEOUS SOLUTION 13
RELISTOR 12 MG/0.6 ML SUBCUTANEOUS SYRINGE 13
RELISTOR 8 MG/0.4 ML SUBCUTANEOUS SYRINGE 13
RESTASIS 0.05 % EYE DROPS IN A DROPPERETTE 7
rivastigmine 13.3 mg/24 hour transdermal patch 15
rivastigmine 4.6 mg/24 hour transdermal patch 15
rivastigmine 9.5 mg/24 hour transdermal patch 15
S
SPIRIVA RESPIMAT 1.25 MCG/ACTUATION SOLUTION FOR INHALATION 9
SPIRIVA RESPIMAT 2.5 MCG/ACTUATION SOLUTION FOR INHALATION 9
SPIRIVA WITH HANDIHALER 18 MCG AND INHALATION CAPSULES 9
STIOLTO RESPIMAT 2.5 MCG-2.5 MCG/ACTUATION SOLUTION FOR INHALATION 10
SYNJARDY 12.5 MG-1,000 MG TABLET 14
SYNJARDY 12.5 MG-500 MG TABLET 14
SYNJARDY 5 MG-1,000 MG TABLET . 14
SYNJARDY 5 MG-500 MG TABLET 14
SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE 14
SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE 14
SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE 14
SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE 14
T
TRINTELLIX 10 MG TABLET 3
TRINTELLIX 20 MG TABLET 3
TRINTELLIX 5 MG TABLET 3
TRULICITY 0.75 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR 8
TRULICITY 1.5 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR 8
U
ULORIC 40 MG TABLET 17
ULORIC 80 MG TABLET 17

V
VICTOZA 3-PAK 0.6 MG/0.1 ML (18 MG/3 ML) SUBCUTANEOUS PEN INJECTOR 8
VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK 3
VIIBRYD 10 MG TABLET 3
VIIBRYD 20 MG TABLET 3
VIIBRYD 40 MG TABLET 3